DRUG STUDY FORM

Initial Complaints: ____________________________________________ Diagnosis/Impression: ____________________________

MECHANISM OF
GENERIC NAME BRAND NAME INDICATION ADVERSE REACTION DOSAGE NURSING CONSIDERATION
ACTION
Assessment
RDA • Megaloblastic anemia:
Adult Assess patient for fatigue,
(pregnant/breastfeeding): dyspnea, weakness, activity
PO 600 mcg/day intolerance (signs of
Adult and child ≥14 yr: megaloblastic anemia)
PO 400 mcg • Monitor Hgb, Hct, and
Child 9-13 yr: PO 300 mcg reticulocyte count; folate
Folic Acid Folvite Needed for Megaloblastic or CNS: Confusion, Child 4-8 yr: PO 200 mcg levels: 6-15 mcg/ml baseline,
(vitamin B9) (PO, erythropoiesis; increases macrocytic anemia depression, excitability, Child 1-3 yr: PO 150 mcg throughout treatment
OTC; IM/IV, Ph) RBC, WBC, and platelet caused by folic acid irritability Infant 6 mo-1 yr: PO 80 • Assess nutritional status:
formation in deficiency; liver GI: Anorexia, nausea mcg bran, yeast, dried beans, nuts,
megaloblastic anemias disease; alcoholism; INTEG: Flushing, Neonate and infant <6 fruits, fresh vegetables,
Therapeutic outcome: hemolysis; intestinal pruritus, rash, erythema mo: PO 65 mcg asparagus; if high folic acid
Absence of macrocytic, obstruction; RESP: Bronchospasm Megaloblastic/macrocyti foods are missing from the
megaloblastic anemias pregnancy; to reduce SYST: Anaphylaxis c anemia due to folic diet, a referral to a dietitian
risk of neural tube (rare) acid or nutritional may be indicated
defect deficiency
Pregnant/lactating: PO
800-1000 mcg
Therapeutic dose
Adult and child:
PO/IM/SUBCUT/IV up to 1
mg/day
Maintenance dose
Adult and child >4 yr:
PO/IM/IV/SUBCUT 0.4
mg/day
Child <4 yr:
 PO/IM/IV/SUBCUT up to
0.3 mg/ day
Infant: PO/IM/IV/SUBCUT
up to 0.1 mg/day
Pregnant/lactating:
PO/IM/IV/SUBCUT 0.8-1
mg/day
Prevention of neural
tube defects during
pregnancy
Adult: PO 0.6 mg/day
Prevention of
megaloblastic anemia
during pregnancy
Adult: PO/IM/SUBCUT up
to 1 mg/day during
pregnancy
Tropical sprue
Adult: PO 3-15 mg/day

Precaution:  Assess pt’s pain before

Aspirin- like drug that Relief of pain If rash occurs, Adult: start with 75-150 therapy
Mefenamic Acid Dolfenal has analgesic, including muscular, administration should be mcg BID  Monitor for possible
antipyretic & anti- rheumatic, traumatic, stopped, asthmatics, Hx drug induced adverse
inflammartory activities dental, post-op and of liver and kidney Severe HPN 300 BID recations
postpartum pain, disease  Advise pt. not to take
headache, migraine, Adverse RXN: drug for more that 7
fever, dysmenorrhea GL discomfort diarrhea days
or constipation, gas pain,  Advice pt. to report
nausea, vomiting, immediately
drowsiness persistence or failure to
relieve pain
Heparin Beprin Prevents conversion Prevention and CNS: Fever, chills, Assessment
of fibrinogen to treatment of MI, headache Deep vein • Assess for blood studies
fibrin and open heart GU: Hematuria thrombosis/pulmonary (Hct, occult blood in stools)
prothrombin to surgery, HEMA: Hemorrhage, embolism q3mo if patient is on long-term
thrombin by disseminated thrombocytopenia, Adult: IV BOL 80 therapy
enhancing inhibitory intravascular clotting anemia, HIT international units/kg, then • Monitor PPT, which should
effects of antithrombin III syndrome, atrial INTEG: Rash, maintenance IV INF 18 be 1½-2 3 control, PTT; often
Therapeutic outcome: fibrillation with dermatitis, urticaria, international units/ kg/hr; if done daily, APTT, ACT
Prevention of embolization; as an pruritus, delayed aPTT <35 (1.23normal), • Monitor platelet count q2-
thrombi anticoagulant in transient alopecia, increase IV INF rate by 4 3day; thrombocytopenia may
transfusion and hematoma, cutaneous international units/kg/hr occur on fourth day of
dialysis procedures; necrosis (SUBCUT), and rebolus with 80 treatment and resolve, or
to maintain patency of injection site reactions international units/kg; if continue to eighth day of
indwelling META: Hyperlipidemia aPTT 35-45 (1.2-1.5 X treatment
venipuncture devices; SYST: Anaphylaxis normal), increase IV INF • Monitor for hypersensitivity:
diagnosis, treatment by 2 international fever, skin rash, urticaria;
of disseminated units/kg/hr and rebolus notify prescriber immediately
intravascular with 40 international
coagulation (DIC) units/kg; if aPTT 46-70
(1.5-2.3 X normal),
maintain IV INF; if aPTT
71-90 (2.3-3 X normal),
decrease IV INF by 2
international units/kg/hr; if
aPTT >90 (>3 X normal),
hold IV INF for 1 hr, then
decrease rate 3
international units/kg/hr
Child/infant/neonate: IV
loading dose 75
international units/kg
Child >1 yr: 20
international units/kg/hr,
infant, neonate <1 yr: 28
international units/ kg/hr as
initial maintenance dose

Thrombosis prophylaxis
(open heart/CV surgery)
Adult: IV ≥150
international units/kg,
procedures <60 min up to
300 international units/ kg,
procedures >60 min up to
400 international units/kg,
based on ACT
Thrombosis prophylaxis
(PCI, not receiving
abciximab)
Adult: IV BOL weight-
adjusted with 60-100
international units/kg,
maintain ACT within 250-
300 sec (HemoTec) or
300-350 sec (Hemochron)
Child/infant/neonate: IV
BOL 100-150 international
units/kg
Prophylaxis for DVT/PE
Adult: SUBCUT 5000 units
q8-12hr
IV catheter occlusion
prophylaxis
Adult and child: IV 10-
100 units/ml
Infant <10 kg: IV 10
units/ml
Prepared by: Noted By:
___
____ _____ Clinical Instructor
Name of Student